Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | CNR2 | P34972 | 6/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125738 | 0.93 | ESR1 (0.40) | HDAC3ESR1MTNR1ASMN1; SMN2 | |
| SCHEMBL2133190 | 0.84 | TNF (0.48) | CNR1CNR2 | |
| SCHEMBL3469887 | 0.83 | CSNK2A2 (0.44) | HDAC3CSNK2A2CSNK2A1MAPK13MAPK12 | |
| SCHEMBL2125588 | 0.79 | FPR2 (0.41) | CNR2 | |
| SCHEMBL2616388 | 0.75 | ESR1 (0.44) | ESR1MTNR1ASMN1; SMN2 | |
| SCHEMBL18638435 | 0.73 | CAMKK1 (0.38) | KDM4E | |
| SCHEMBL15646004 | 0.70 | ITGB3 (0.38) | CNR1CNR2KDM4E | |
| SCHEMBL21137545 | 0.70 | NOTUM (0.43) | CSNK2A2CSNK2A1MAPK13MAPK12MAPK11 | |
| SCHEMBL28922916 | 0.70 | MTNR1A (0.59) | CSNK2A2CSNK2A1CNR2ESR1MTNR1A | |
| SCHEMBL18638434 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443115-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010145201-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101123-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | HDAC3 483/4885CSNK2A2 749/4885CSNK2A1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.